Reliability and Validity of the Subjective Cognitive Complaints Questionnaire for Parkinson’s Disease (SCCQ-PD)

Background and Purpose Subjective cognitive complaints (SCCs) are gaining attention as a self-perceived symptom for cognitive impairment in patients with Parkinson’s disease (PD), but there are few suitable tools for assessing SCCs in PD. This study aimed to develop and validate a questionnaire for assessing SCCs in PD, called the Subjective Cognitive Complaints Questionnaire for Parkinson’s Disease (SCCQ-PD).

Methods The SCCQ-PD consists of 12 yes/no questions on subjective cognitive function, and the questionnaire was completed by patients with PD (score-P) and their caregivers (score-C). The cognitive function of patients was examined using comprehensive neuropsychological tests.

Results This study included 73 patients (38 cognitively normal, 25 with mild cognitive impairment [MCI], and 10 demented) and their caregivers. Score-P and score-C had excellent reliability (Kuder-Richardson formula 20 coefficients of 0.893 and 0.931, respectively), and the scores exhibited a strong intercorrelation. Both score-P and score-C were negatively correlated with cognitive performance, and both were excellent in discriminating demented patients from those with normal cognition or MCI (areas under the receiver operating characteristic curve of 0.83 and 0.88, respectively).

Conclusions The SCCQ-PD is a reliable tool for assessing SCCs in patients with PD. SCCs measured using the SCCQ-PD are correlated with objective cognitive decline and useful for discriminating demented patients from nondemented patients.

Keywords Parkinson’s disease; cognitive decline; cognition.

INTRODUCTION

Parkinson’s disease (PD) is characterized by motor symptoms, but nonmotor symptoms also affect the daily living of patients with PD. Cognitive impairment is one of the most-disabling complications in PD, and dementia develops in most patients with advanced PD. The concept of mild cognitive impairment (MCI) in PD is well established, and regarded as a predementia status. Furthermore, subjective experiences of cognitive decline, termed subjective cognitive complaints (SCCs), in the absence of obvious cognitive impairment have been tested as a potential predictor of subsequent cognitive deterioration. Although there is controversy about the predictive value of SCCs, more studies are investigating SCCs in both Alzheimer’s disease (AD) and PD.

There are no reliable imaging or neurochemical biomarkers for SCCs, and so they have only been assessed using a simple question or questionnaire. Several questionnaires for SCCs have been developed, but most focus on memory complaints because the concept of SCCs originated from cognitive impairment due to AD. However, PD affects not only memory function but also other cognitive domains including attention, executive function, and vis-sensory integration.
suospatial ability from the early phase of cognitive decline.\textsuperscript{12-14} Therefore, a questionnaire for SCCs in PD should contain items assessing the subjective feeling related to various aspects of cognitive function beyond memory.

Several previous studies have found that the self-rated scores on questionnaires for SCCs tend to be lower for patients with dementia than for patients with MCI, with caregivers tending to assign higher scores for patients with dementia than for patients with MCI.\textsuperscript{8,10} The authors attributed this discrepancy to demented patients lacking awareness of their cognitive deterioration. However, it is unclear whether “cognitive anosognosia”\textsuperscript{15} is present in patients with PD, and so this needs to be explored further.

In this study, we developed a self-reported questionnaire for SCCs in PD, called the Subjective Cognitive Complaints Questionnaire for Parkinson’s Disease (SCCQ-PD). We compared SCCQ-PD scores between those rated by patients with PD and those rated by their caregivers, and validated its reliability and its ability to predict the cognitive level in patients with PD.

**METHODS**

**Subjects**
The study subjects were enrolled consecutively between November 2017 and January 2019 from a neurology outpatient clinic of a tertiary referral center. All patients were diagnosed with PD based on the criteria of the United Kingdom PD Society Brain Bank\textsuperscript{16} prior to enrollment into this study. To exclude dementia with Lewy bodies, patients who developed visual hallucinations or cognitive problems that impaired their social or occupational activities before or within 1 year of the onset of motor symptoms were not enrolled. Patients who had a vascular lesion or mass in the basal ganglia revealed by magnetic resonance imaging were also excluded from the study. Medical records were searched for the presence of a medical history, and atrophy of the medial temporal lobe was evaluated using a visual rating scale.\textsuperscript{17}

This study received approval for human experimentation from the Institutional Review Board of the Yonsei University Wonju Severance Christian Hospital where the subjects were enrolled (approval number: CR317099), and written informed consent was obtained from all of the included patients and their caregivers. The caregivers were restricted to family members who lived with the patients and were not demented.

**Design of the SCCQ-PD**
The SCCQ-PD consists of 12 yes/no questions on subjective feelings about the everyday cognition of patients. Patients and caregivers were instructed to answer the questions based on their experiences over the previous 6 months. The following questions were selected from items analyzed in previous studies\textsuperscript{7,8,11,18} with modifications to reflect the effects of SCCs in various cognitive domains:

1. Do you have difficulty in remembering where you left things?
2. Have you asked a family member to repeat the details of a recent conversation?
3. Do you often forget appointments?
4. Do you have difficulty in traveling to familiar places or recognizing a previously traveled route?
5. Do you have difficulty using public transportation or remembering a route you have driven often?
6. Do you have difficulty in understanding the speech of other people?
7. Do you have difficulty finding words that you want to say?
8. Has your mathematical ability deteriorated?
9. Do you have difficulty performing bank transactions or paying taxes?
10. Do you have difficulty using home electronics?
11. Have your social activities been reduced or do you need help to go out?
12. Have you become indifferent or less compassionate toward other people?

**Neuropsychological assessment**
A comprehensive neuropsychological assessment were conducted by an experienced neuropsychologist using the following neuropsychological battery to fulfill the Level II criteria for MCI in PD\textsuperscript{3} proposed by the Movement Disorder Society (MDS): backward digit span\textsuperscript{19} and Stroop test (color reading)\textsuperscript{19} for attention, Korean version of the Boston Naming
Test (K-BNT)\textsuperscript{19} and the word similarity test of the Wechsler Adult Intelligence Scale-Fourth Edition\textsuperscript{20} for language function, the copying task of the Rey Complex Figure Test (RCFT)\textsuperscript{19} and clock copying\textsuperscript{21} for visuospatial function, 20-min delayed recall using the Seoul Verbal Learning Test\textsuperscript{19} and the RCFT\textsuperscript{19} for memory, and category fluency (animals) using the Controlled Oral Word Association Test\textsuperscript{19} and the clock-drawing test\textsuperscript{21} for executive function. Additionally, general cognitive function and depressive symptoms were assessed using the Korean version of the Mini-Mental State Examination (K-MMSE),\textsuperscript{22} the Korean version of the Montreal Cognitive Assessment (K-MoCA),\textsuperscript{23} and the Korean version of Beck Depression Inventory-II (K-BDI-II).\textsuperscript{24}

**Diagnosis of MCI and dementia**

MCI was diagnosed based on the criteria for MCI in PD proposed by the MDS (Level II category):\textsuperscript{26} 1) performance on at least 2 of the 10 subtests lower than the mean minus 1.5 standard deviations (SDs) of the normative data corrected for age, sex, and duration of education, and 2) no impairment in the activities of daily living (ADL) assessed using the Korean-Instrumental Activities of Daily Living.\textsuperscript{25} Impairment in ADL due to motor or autonomic symptoms of PD was not reflected to the ADL assessment.

PD with dementia was diagnosed according to the following criteria proposed by the MDS:\textsuperscript{26} 1) the mean z score for two tests in a cognitive domain lower than -1.5 in at least two domains, and 2) impaired ADL.

**Statistical analysis**

Demographic characteristics and neuropsychological performance were compared among the included cognitive groups using one-way analysis of variance and the chi-square test, with Bonferroni’s correction used for post-hoc analyses. The internal consistency reliability and construct validity of the SCCQ-PD were tested using Kuder-Richardson formula 20 and principal-components analysis (PCA). Pearson’s correlation was used to explore the relationships between SCCQ-PD scores and cognitive performance, and partial correlations were analyzed while adjusting for age, sex, duration of education, and K-BDI-II score. The discriminative power of the SCCQ-PD was explored using receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC). All of the statistical analyses were conducted using SPSS Statistics (version 25, IBM SPSS, Armonk, NY, USA).

**RESULTS**

**Subjects and baseline demographics**

This study included 73 patients (34 males and 39 females) and their caregivers. Patients were classified into three groups based on neuropsychological performance: cognitively normal (CN group, n=38), MCI group (n=25), and dementia (DMT group, n=10). The demographic characteristics of study subjects are

| Table 1. Demographic characteristics of patient groups classified according to their cognitive status |
|---------------------------------------------------------------|
| CN (n=38) | MCI (n=25) | DMT (n=10) | p  | Significant pairs |
| Sex (male/female) | 15/23 | 13/12 | 6/4 | 0.409 | - |
| Age (yr) | 73.7±7.2 | 72.8±6.9 | 80.2±5.2 | 0.016 | CN<DMT, MCI<DMT |
| Age at onset of PD (yr) | 69.3±6.2 | 68.4±7.9 | 75.9±6.9 | 0.041 | MCI<DMT |
| Duration of PD (yr) | 4.3±3.2 | 4.4±3.2 | 4.3±2.7 | 0.988 | - |
| UPDRS motor score | 26.4±11.4 | 29.7±11.1 | 33.2±10.7 | 0.331 | - |
| LEDD (mg/day) | 568.4±335.7 | 568.8±362.5 | 722.0±492.0 | 0.479 | - |
| Duration of education (yr) | 5.4±4.3 | 6.6±5.4 | 7.5±5.3 | 0.403 | - |
| K-BDI-II score | 14.4±8.7 | 17.2±10.0 | 17.0±9.9 | 0.465 | - |
| Hypertension | 14 (36.8) | 4 (16.0) | 2 (20.0) | 0.164 | - |
| Diabetes mellitus | 11 (28.9) | 6 (24.0) | 0 (0.0) | 0.155 | - |
| Dyslipidemia | 5 (13.2) | 6 (24.0) | 0 (0.0) | 0.179 | - |
| Medial temporal lobe atrophy score | 0 | 20 (52.6) | 11 (44.0) | 2 (20.0) | 0.062* |
| 1 | 11 (28.9) | 9 (36.0) | 3 (30.0) | - |
| 2 | 5 (13.2) | 4 (16.0) | 4 (40.0) | - |
| 3 | 2 (5.3) | 1 (4.0) | 1 (10.0) | - |
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |

Data are mean±standard-deviation or n (%). values.
*Linear-by-linear association.

CN, cognitively normal; DMT, dementia; K-BDI-II, Korean version of Beck Depression Inventory-II; LEDD, levodopa equivalent daily dose; MCI, mild cognitive impairment; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale.
presented in Table 1. Patients in the DMT group were older than those in the CN and MCI groups, and the age at PD onset was higher in the DMT group than in the MCI group. There were no intergroup differences in sex, duration of PD, motor score on the Unified Parkinson's Disease Rating Scale, levodopa equivalent dose, duration of education, K-BDI-II score, presence of hypertension, diabetes mellitus, or dyslipidemia, or score for medial temporal lobe atrophy. The neuropsychological performance of the subjects is presented in Supplementary Table 1 (in the online-only Data Supplement).

SCCQ-PD scores
Score-P was higher in the DMT group (9.3±3.4, mean±SD) than in the CN (4.4±3.6) or MCI (4.6±3.3) group, and did not differ significantly between the CN and MCI groups (Table 2). Score-C also was higher in the DMT group (9.6±3.2) than in the CN (3.2±4.0) and MCI (4.0±3.6) groups. The differences between score-P and score-C were similar across the three groups, and score-P and score-C were strongly correlated with each other ($r=0.69, p<0.001$).

| Score  | CN (n=38)   | MCI (n=25) | DMT (n=10) | p    | Significant pairs               |
|--------|-------------|------------|------------|------|---------------------------------|
| Score-P| 4.4±3.6     | 4.6±3.3    | 9.3±3.4    | 0.001| CN<DMT, MCI<DMT                 |
| Score-C| 3.2±4.0     | 4.0±3.6    | 9.6±3.2    | <0.001| CN<DMT, MCI<DMT                |
| Score-P + score-C | 7.6±7.0 | 8.6±6.0 | 18.9±5.5 | <0.001| CN<DMT, MCI<DMT                |
| Score-P – score-C | 1.3±2.9 | 0.6±3.5 | -0.3±3.8 | 0.372| N/A                             |

Data are mean±standard-deviation values.

CN, cognitively normal; DMT, dementia; MCI, mild cognitive impairment; N/A, not applicable; score-C, score rated by caregivers; score-P, score rated by patients.

Internal consistency reliability
The Kuder-Richardson formula 20 coefficient was 0.893 for score-P and 0.931 for score-C. Corrected item-total correlation coefficients for all items exceeded 0.4 (range=0.46–0.78) and 0.6 (range=0.63–0.79) for patients and caregivers, respectively.

Construct validity
The PCA of score-P revealed two components with eigenvalue >1 (5.555 and 1.225), which explained 46.3% and 10.2% of the variance, respectively (Kaiser-Meyer-Olkin [KMO] value=0.879, Bartlett’s test statistic for sphericity <0.001). The PCA of score-C identified one component with eigenvalue >1 (6.853), which explained 57.1% of the variance (KMO value=0.914, Bartlett’s test statistic for sphericity <0.001). Scree plots for score-P and score-C both showed sharp decreases in eigenvalues after the first factor (Fig. 1).

Correlation between SCCQ-PD score and neuropsychological performance
Score-P was negatively correlated with the K-MMSE score, K-MoCA score, and the performance on all items of the neuropsychological tests.

![Fig. 1. Scree plots from exploratory factor analyses of the scores on the Subjective Cognitive Complaints Questionnaire for Parkinson’s Disease (SCCQ-PD) for patients with Parkinson’s disease (score-P) (A) and their caregivers (score-C) (B). A sharp decrease in the eigenvalues after the first component was evident on both scree plots.](image-url)
ropsychological battery, and was strongly positively correlat-

ed with the K-BDI-II score (Table 3 and Fig. 2). When the
covariates (age, sex, duration of education, and K-BDI-II
score) were adjusted, score-P was correlated with the K-MMSE
score, K-MoCA score, and the performance on the K-BNT,
copying task of RCFT, clock copying, delayed recall on the
RCFT, and clock-drawing test.

Score-C was negatively correlated with the K-MMSE score,
K-MoCA score, and the performance on all items of the neu-
ropsychological battery, and positively correlated with the
BDI-II score (Table 3 and Fig. 2). After adjusting for covari-
ates, score-C was correlated with the K-MMSE score, K-Mo-
CA score, the performance on the Stroop test (color reading),
copying task of RCFT, clock copying, delayed recall on the
RCFT, category fluency test (animals), and clock-draw-
ing test.

**DISCUSSION**

This study has developed and validated the SCCQ-PD, a ques-
tionnaire that assesses SCCs in patients with PD. The results
showed that the SCCQ-PD is a reliable and useful self-rating
tool for screening dementia.

Because cognitive impairment affects multiple cognitive do-

main in patients with PD,12-14 self-perceived cognitive com-
plaints should be accessed regarding not only memory func-
tion but also other types of cognitive functioning. New tools
for SCCs in patients with PD were recently examined for as-
seSSing all cognitive domains.27,28 The SCCQ-PD developed
in the present study was also designed to reflect diverse as-
pects of cognitive function: memory, visuospatial function,
language, executive function, and neuropsychiatric function.26
These tools seem to be suitable for SCCs in PD, but further
studies are required to confirm their practical usefulness.

Many previous studies have found that dementia patients
show poor insight into their cognitive impairment15,29 and
that the correlations between cognitive complaints and ob-
jective cognitive dysfunction were stronger for reports by in-
formants than for patient self-reporting.9,10,29,30 However, Si-
tek et al.31 reported that self-awareness of memory function
is preserved well in patients with PD. Similarly, the present
study found that SCCQ-PD scores rated by patients and care-

### Table 3. Correlations between SCCQ-PD scores and neuropsychological performance

|                  | Uncorrected | Corrected |
|------------------|-------------|-----------|
|                  | Score-P     | Score-C   | Score-P | Score-C |
|                  | rho p       | Partial rho p | rho p       | Partial rho p |
| K-MMSE           | -0.461 <0.001 | -0.360 0.002 | -0.339 0.004 |
| K-MoCA           | -0.489 <0.001 | -0.379 0.001 | -0.350 0.003 |
| Backward digit span | -0.326 0.005 | -0.179 0.142 | -0.094 0.442 |
| Stroop–color reading | -0.351 0.003 | -0.228 0.068 | -0.427 <0.001 |
| K-BNT            | -0.376 0.001 | -0.302 0.012 | -0.181 0.136 |
| Word similarity  | -0.254 0.030 | -0.091 0.456 | -0.187 0.125 |
| Copying task of RCFT | -0.357 0.002 | -0.297 0.013 | -0.282 0.019 |
| Clock copying    | -0.288 0.013 | -0.244 0.043 | -0.310 0.010 |
| Delayed recall (visual) | -0.343 0.003 | -0.170 0.163 | -0.200 0.100 |
| Category fluency | -0.247 0.035 | -0.114 0.351 | -0.279 0.021 |
| Clock-drawing test | -0.322 0.005 | -0.265 0.027 | -0.380 0.001 |
| K-BDI-II         | 0.465 <0.001 | 0.384 0.001 |          |

K-BDI-II, Korean version of Beck Depression Inventory-II; K-BNT, Korean version of the Boston Naming Test; K-MMSE, Korean version of the Mini-
Mental State Examination; K-MoCA, Korean version of the Montreal Cognitive Assessment; RCFT, Rey Complex Figure Test; SCCQ-PD, Subjective Cog-
nitive Complaints Questionnaire for Parkinson’s Disease; score-C, score rated by caregivers; score-P, score rated by patients.
givers were comparable. It is unclear why cognitive anosognosia is absent in patients with PD, but this might be due to differences in the pathophysiology of cognitive impairment between AD and PD.

Both score-P and score-C were strongly correlated with the K-MMSE score, K-MoCA score, and all subsets of the neuropsychological battery. While many previous studies have found significant correlations between SCCs and cognitive performance, several studies did not. This discrepancy could be due to differences in methodologies, including in the assessment of SCCs, cognitive level of subjects, neuropsychological tests, and adjusted factors. SCCs in both AD and PD have been reported to be associated with psychiatric symptoms, especially depression. This was also observed in
the present study, with both score-P and score-C being strongly correlated with the depression score. However, after adjustment for covariates including depression score, both score-P and score-C were correlated with the K-MMSE and K-MoCA scores as well as the performance in approximately half of the items of the neuropsychological battery. Therefore, the SCCQ-PD score is correlated with cognitive performance independently of depression severity.

The ROC curves showed that both score-P and score-C have excellent discriminative power, and both scores have the same optimal criterion of ≥8 for a diagnosis of dementia. Indeed, both scores increase as cognitive level declines, and the two scores exhibit a moderate intercorrelation. SCCQ-PD scores were significantly higher in patients with dementia than in those with normal cognition or MCI, while they did not differ significantly between the cognitively normal and MCI patients. This pattern has also been observed in a previous study, which found that the Cognitive Complaint Interview (CCI), a SCC questionnaire, was excellent in discriminating dementia but not MCI from normal cognition.32 Dujardin et al.14 reported that the CCI is poor in discriminating cognitive impairment from normal cognition. These findings indicate that SCCs are useful for detecting dementia but not MCI. In the same context, several previous studies involving patients with normal cognition35-38 and MCI36 but not dementia did not observe significant differences in cognitive performance between patients with and without SCCs.

This study had several limitations. First, the number of subjects was relatively small, especially for patients with dementia. Second, the study subjects were relatively old and had a relatively short duration of education, and so floor effects of the K-MMSE and K-MoCA might have weakened in the findings. Third, it is unclear whether SCCs measured by the SCCQ-PD are clinically meaningful. Further studies are therefore needed to test the relationship between SCCQ-PD scores and pathological burden, and to explore the predictive value of the SCCQ-PD for long-term cognitive decline. Finally, this study did not include pathological data or functional neuroimaging data, and hence it is possible that coexisting beta-amyloid pathology was present.39,40

In summary, the SCCQ-PD is a reliable tool for assessing SCCs in patients with PD. SCCQ-PD scores rated by patients and caregivers were both strongly correlated with the objective cognitive performance of patients, and therefore useful for discriminating between patients with and without dementia.

Supplementary Materials

The online-only Data Supplement is available with this article at https://doi.org/10.3988/jcn.2022.18.2.171.

Availability of Data and Material

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

ORCID iDs

Jeongmin Ko https://orcid.org/0000-0001-5699-4014
Joonyoung Ha https://orcid.org/0000-0002-6138-3995
Jae Jung Lee https://orcid.org/0000-0001-6799-1564
Sunjin Jin https://orcid.org/0000-0002-6508-5434
Jongwoo Lee https://orcid.org/0000-0003-2201-5839
Min Seok Baek https://orcid.org/0000-0001-5250-9480
Jin Yong Hong https://orcid.org/0000-0002-2476-3737

Author Contributions

Conceptualization: Jae Jung Lee, Jin Yong Hong. Data curation: Jeongmin Ko, Joonyoung Ha, Sunjin Jin, Jongwoo Lee. Funding acquisition: Jin Yong Hong. Investigation: Jeongmin Ko, Joonyoung Ha, Sunjin Jin, Jongwoo Lee. Methodology: Jeongmin Ko, Jae Jung Lee, Min Seok Baek, Jin Yong Hong. Project administration: Jeongmin Ko, Jae Jung Lee, Min Seok Baek, Jin Yong Hong. Resources: Jin Yong Hong. Software: Min Seok Baek, Jin Yong Hong. Supervision: Jin Yong Hong. Validation: Jae Jung Lee, Min Seok Baek, Jin Yong Hong. Visualization: Jeongmin Ko, Jin Yong Hong. Writing—original draft: Jeongmin Ko. Writing—review & editing: Joonyoung Ha, Jae Jung Lee, Sunjin Jin, Jongwoo Lee, Min Seok Baek, Jin Yong Hong.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Funding Statement

This work was supported by the Chong Kun Dang Pharmaceutical Corporation, Seoul, Korea.
REFERENCES

1. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312.
2. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
3. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.
4. Jessen F, Amariiglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 2014;10:844-852.
5. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982;21:1-16.
6. Crook TH 3rd, Larrabee GJ. A self-rating scale for evaluating memory in everyday life. Psychol Aging 1990;5:48-57.
7. Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties. Neuropsychology 2008;22:531-544.
8. Jorm AF. The informant questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr 2004;16:275-293.
9. Rami L, Mollica MA, García-Sánchez C, Saldáñez J, Sanchez B, Sala I, et al. The Subjective Cognitive Decline Questionnaire (SCD-Q): a validation study. J Alzheimers Dis 2014;41:453-466.
10. Rattanabannakit C, Risacher SL, Gao S, Lane KA, Brown SA, McGeer E, et al. The clinical usefulness for various neurodegenerative diseases. Dement Neuropsychol Disord 2018;17:11-22.
11. Youn JC, Kim KW, Lee DY, Jhoo JH, Lee SB, Park JH, et al. Development of the SCCQ-PD.
12. Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:308-312.
13. Kalbe E, Rehberg SP, Heber I, Kronenbuerger M, Schulz JB, Storch A, et al. Subjective cognitive complaints in Parkinson disease: a preliminary study. Appl Neuropsychol Adult 2015;22:287-292.
14. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive dementia and dementia in patients with Parkinson's disease. Lancet Neurol 2010;9:1200-1213.
15. Barrett AM, Edinger PJ, Mallentite NH, Hellman KM. Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology 2005;64:693-699.
16. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
17. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vempers P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-972.
18. Dujardin K, Duhamel A, Dellaux M, Thomas-Antérion C, Déstée A, Defebvre L. Cognitive complaints in Parkinson's disease: its relationship with objective cognitive decline. J Neurol 2010;257:79-84.
19. Kang Y, Jahng S, Na DL. Seoul neuropsychological screening battery. 2nd ed. Seoul: Human Brain Research & Consulting, 2012.
20. Kwak W, Kim J, Park G, Choi J, Hong S. Korean Wechsler adult intelligence scale-IV. Daegu: Korea Psychology, 2012.
21. Kim SG, Lee DY, Seo EH, Choo IH, Kim JW, Do YJ, et al. A normative study of an executive Clock Drawing Task (CLOX) in Korean elderly. J Korean Neuropsychiatr Assoc 2009;48:437-446.
22. Kang Y, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc 1997;15:300-308.
23. Kang Y, Park JS, Yu KH, Lee BC. A reliability, validity, and normative study of the Korean-Montreal Cognitive Assessment (K-MoCA) as an instrument for screening of vascular cognitive impairment (VCI). Korean J Clin Psychol 2009;28:549-562.
24. Lim SY, Lee EJ, Jeong SW, Kim HC, Jeong CH, Jeon TY, et al. The validation study of Beck Depression Scale 2 in Korean version. Anxity and Mood 2011;7:48-53.
25. Chin J, Park J, Yang SJ, Yoon J, Ahn Y, Baek MJ, et al. Re-standardization of the Korean-Instrumental Activities of Daily Living (K-IADL): clinical usefulness for various neurodegenerative diseases. Dement Neuropsychol Disord 2018;17:11-22.
26. Dubois B, Burn D, Goetz C, Aarsland D, Brown NG, Broe GA, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22:2314-2324.
27. Dupouy J, Orly-Magne F, Mel eties C, Rousseau V, Puel M, Rerat K, et al. Cognitive complaint in early Parkinson's disease: a pilot study. Acta Neuro Scand 2018;13:79-96.
28. Koster DP, Higginson CI, MacDougall EE, Wheelock VL, Sigvardt KA. Subjective cognitive complaints in Parkinson disease without dementia: a preliminary study. Appl Neuropsychol Adult 2015;22:287-292.
29. Slavin MJ, Brodaty H, Kochan NA, Crawford JD, Trolle NR, Draper B, et al. Prevalence and predictors of “subjective cognitive complaints” in the Sydney Memory and Ageing Study. Am J Geriatr Psychiatry 2010;18:701-710.
30. Carr DB, Gray S, Baty J, Morris JC. The value of informant versus individual's complaints of memory impairment in early dementia. Neurology 2000;55:1724-1726.
31. Slet Ed, Soltan W, Wiszorek D, Bobowski P, Slawek J. Self-awareness of memory function in Parkinson's disease in relation to mood and symptom severity. Aging Ment Health 2011;15:150-156.
32. Hong JY, Lee Y, Sunwoo MK, Sohn YH, Lee PH. Subjective cognitive complaints and objective cognitive impairment in Parkinson's disease. J Clin Neurol 2018;14:16-21.
33. Woods DT, Kneebone AC. Memory problems in Parkinson's disease patients with and without mild cognitive impairment: comparisons between caregiver and self-report. Mov Disord Clin Pract 2017;4:430-436.
34. Copeland JN, Lieberman A, Oravivattanakul S, Töröster AI. Accuracy of patient and care partner identification of cognitive impairments in Parkinson disease—mild cognitive impairment. Mov Disord 2016;31:693-698.
35. Erro R, Santangelo G, Barone P, Picillo M, Amboni M, Longo K, et al. Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease? J Geriatri Psychiatry Neurology 2014;27:276-281.
36. Lehrer J, Moser D, Klug S, Gleiß A, Auff E, Pirker W, et al. Subjective memory complaints, depressive symptoms and cognition in Parkinson's disease patients. Eur J Neurol 2014;21:1276-1284.
37. Hodge J, Evans J, Lees EA, Wooton R, Scott J, Woodhouse C, et al. Subjective cognitive decline predicts future deterioration in cognitively normal patients with Parkinson's disease. Neurobiol Aging 2014;35:1739-1743.
38. Foster RB, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010;25:2516-2523.
39. Jellinger KA. Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008;115:427-436.